EQT Life Sciences leads USD 56 million Series D financing in Neuros Medical to commercialize FDA-approved treatment for post-amputation pain

Contributed by: PR Newswire

Tags

EQT-Financing

More Like This

EQT Life Sciences Leads Series B Extension in Noema Pharma, Raising Total Series B Financing to CHF 130 million

EQT Life Sciences Co-Leads USD 135 Million Series B Financing in SpliceBio

EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round

EQT Life Sciences leads USD 75 million Series B in Atalanta Therapeutics, a biotech firm developing treatments for epilepsy and Huntington's disease

EQT Life Sciences leads Series A funding round for maternal health company Nua Surgical

EQT Life Sciences leads €54 Million Series A Financing of ATB Therapeutics

PR Newswire associated0

Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion Globally

“The NEUROFUSE Study has yielded promising early clinical results consistent with preclinical studies of NTX-001,” said Evan Tzanis, Chief Operating Officer and EVP of R&D at Neuraptive Therapeutics, Inc. (Photo: Business Wire)

Neuraptive Therapeutics, Inc. Announces Achievement of Proof of Concept in The NEUROFUSE Study of NTX-001 for the Adjunct Treatment of Transected Peripheral Nerves